Trial Profile
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Folinic acid (Primary) ; Fosifloxuridine nafalbenamide (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms NuTide:302
- Sponsors NuCana
- 02 Apr 2024 Status changed from recruiting to completed.
- 13 Oct 2023 According to a NuCana media release, this study is in part 3 part of the study.
- 13 Oct 2023 According to a NuCana media release, data from this study were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023.